I am an environmental toxicologist and the AstraZeneca global lead for the development of innovative science to support future environmental risk assessments and secure the environmental safety (eco-toxicology) of pharmaceuticals; fundamental for sustainability.
As a comparative physiologist and expert fish biologist, I lead the mode-of-action driven investigations that provide a mechanistic understanding of how human pharmaceuticals may work in animals so as to better predict the possible risks to wildlife.
I am passionate about research to drive the aquatic safety testing paradigm away from animal studies. I do this by investigating new alternative approaches such as using cells to build 3D organoid tissues in culture. At AstraZeneca I am the global lead for the 3Rs (reduction, replacement and refinement) of animal studies and I am proud to chair the prestigious AstraZeneca awards that help share the innovation from these teams.
I am privileged to work with some of the leading academics and opinion formers in my field and have published more than 65 scientific papers. I work extensively supporting early career scientists and I am an Honorary Associate Professor in the College of Life and Environmental Sciences at the University of Exeter. In 2021 I joined the independent Hazardous Substances Advisory Committee for the UK Government, bringing expertise in New Approach Methods to support future chemical assessments.
By collaborating with some of the best scientists and leaders in academia, regulators and industry I am working towards finding better ways to predict the potential impacts of chemicals in the environment.
Hon Associate Professor, University of Exeter.
Hazardous Substances Advisory Committee (HSAC)
Independent Member of UK Government Defra Advisory
AstraZeneca Council for Science and Animal Welfare
Invited to join the UK Government Defra Hazardous Substances Advisory Committee (HSAC) to share expertise in New Approach Methods to support future chemical assessments.
Published a book chapter on how to use artificial intelligence and machine learning innovations to better protect the environment from chemicals.
‘Prioritisation and Risk Evaluation of Medicines in the EnviRonment (PREMIER)’, a European Union Innovative Medicines Initiative (IMI) Joint Undertaking where I act as an industry lead and designated Ethics Officer.
Beyond the patient: Advanced techniques to help predict the fate and effects of pharmaceuticals in the environment.
Chapter 11 by Owen & Snape in: The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry. Academic Press, 2021, Pages 217-235, ISBN 9780128200452.